The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

Moreover, companies like Viking Therapeutics are advancing a new platform that combines GLP-1 and gastric inhibitory polypeptide (GIP) agonists. Recent data suggests this combination has the ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 61% from its peak value. Despite ...

U.S. President Donald Trump on Wednesday played up prospects of a "fair deal" on trade with China, but his top officials offered few details of how Washington might de-escalate its damaging tariff ...

Of these, 20% were GLP-1 drugs alone, with a host of other combinations such as GLP-1/gastric inhibitory peptide ... healthcare system and regulatory pathways are allowing its life sciences ...

Considering the complexity of T2D pathogenesis, the analysts conducting the study hypothesized that DMR may exert a regulatory effect on metabolic processes via multiple pathways (1 ... levels of ...

Isolation and Identification of Compounds from Bioactive Extracts of Taraxacum officinale Weber ex F. H. Wigg. (Dandelion) as a Potential Source of Antibacterial Agents.